bemdaneprocel
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinsons Disease (PD)
Conditions
Parkinsons Disease (PD)
Trial Timeline
Jun 17, 2025 → Mar 1, 2032
NCT ID
NCT06944522About bemdaneprocel
bemdaneprocel is a phase 3 stage product being developed by Bayer for Parkinsons Disease (PD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06944522. Target conditions include Parkinsons Disease (PD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06944522 | Phase 3 | Recruiting |
Competing Products
5 competing products in Parkinsons Disease (PD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| Rivastigmine Patch 9.5 cm2 | Novartis | Approved | 85 |
| Prasinezumab + Placebo | Roche | Phase 2 | 52 |
| ALN-SNCA + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule | Anavex Life Sciences | Phase 2 | 44 |